Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
DE000A1EWVY8
Fri, 27.09.2024       Formycon AG
DE000A1EWVY8

Disclosure of inside information according to Article 17 of the Regulation (EU) No 596/2014 FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz) Planegg-Martinsried, Germany, September 27, 2024 – Formycon AG (FSE: FYB, "Formycon“) announces that the U.S. Food and Drug Administration (“FDA”) today approved FYB202/OtulfiTM [ … ]
Technical analysis
To the publication
Tue, 06.08.2024       Formycon AG
DE000A1EWVY8

Disclosure of inside information according to Article 17 of the Regulation (EU) No 596/2014 Formycon AG increases its outlook for the 2024 fiscal year Planegg-Martinsried, Germany, August 06, 2024 – Formycon AG (ISIN: DE000A1EWVY8 / WKN: A1EWVY) (“Company”) has today decided, based on the preliminary half-year figures, to raise its guidance for t [ … ]
Technical analysis
To the publication
Fri, 26.07.2024       Formycon AG
DE000A1EWVY8

Disclosure of inside information according to Article 17 of the Regulation (EU) No 596/2014 Stelara® Biosimilar Candidate FYB202 (Ustekinumab) receives positive CHMP opinion from EMA Planegg-Martinsried, Germany, July 26, 2024 – Formycon AG (FSE: FYB, "Formycon“) announces that the Committee for Medicinal Products for Human Use („CHMP“) of the Eu [ … ]
Technical analysis
To the publication
Fri, 28.06.2024       Formycon AG
DE000A1EWVY8

Disclosure of inside information according to Article 17 of the Regulation (EU) No 596/2014 FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb) Planegg-Martinsried, Germany, 28. June 2024 – Formycon AG (FSE: FYB, “Formycon”) and its licensing partner Klinge Biopharma GmbH ("Klinge") announce that the U.S. Food and D [ … ]
Technical analysis
To the publication
Fri, 28.06.2024       Formycon AG
DE000A1EWVY8

Disclosure of inside information according to Article 17 of the Regulation (EU) No 596/2014 FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb) Planegg-Martinsried, Germany, 28. June 2024 – Formycon AG (FSE: FYB, “Formycon”) and its licensing partner Klinge Biopharma GmbH ("Klinge") announce that the U.S. Food and D [ … ]
Technical analysis
To the publication
Fri, 12.04.2024       Formycon AG
DE000A1EWVY8

Disclosure of inside information according to Article 17 of the Regulation (EU) No 596/2014 Formycon AG publishes preliminary figures for the 2023 financial year and guidance for the 2024 financial year Planegg-Martinsried, Germany, 12. April 2024 – Based on preliminary and unaudited figures for the 2023 financial year, Formycon AG (ISIN: DE000A1 [ … ]
Technical analysis
To the publication
Mon, 29.01.2024       Formycon AG
DE000A1EWVY8

NOT FOR DISTRIBUTION, PUBLICATION OR TRANSMISSION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION, PUBLICATION OR TRANSMISSION WOULD BE UNLAWFUL. FURTHER RESTRICTIONS APPLY. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT. Disclosure of i [ … ]
Technical analysis
To the publication
Thu, 02.02.2023       Formycon AG
DE000A1EWVY8

NOT FOR DISTRIBUTION, PUBLICATION OR TRANSMISSION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION, PUBLICATION OR TRANSMISSION WOULD BE UNLAWFUL. FURTHER RESTRICTIONS APPLY. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PUBLICATION.Publication of ins [ … ]
Technical analysis
To the publication
Thu, 02.02.2023       Formycon AG
DE000A1EWVY8

NOT FOR DISTRIBUTION, PUBLICATION OR TRANSMISSION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION, PUBLICATION OR TRANSMISSION WOULD BE UNLAWFUL. FURTHER RESTRICTIONS APPLY. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PUBLICATION.Publication of ins [ … ]
Technical analysis
To the publication
Wed, 01.02.2023       Formycon AG
DE000A1EWVY8

NOT FOR DISTRIBUTION, PUBLICATION OR TRANSMISSION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION, PUBLICATION OR TRANSMISSION WOULD BE UNLAWFUL. FURTHER RESTRICTIONS APPLY. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PUBLICATION.  Publication of  [ … ]
Technical analysis
To the publication

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

Legend/Explanation
The newswire feed is updated several times a day. To make sure you don't miss any news, please check back here often. If you are curious about a headline or want to find out more about a publication, click on it to go to the preview and click again to go to the full news item.
Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Saturday, 05.10.2024, Calendar Week 40, 279th day of the year, 87 days remaining until EoY.